You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB05739
DescriptionCYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.
Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
UNIINot Available
CAS numberNot Available
IndicationInvestigated for use/treatment in hypertension.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionThe so called renin-angiotensin system (RAS) is an important regulator of blood pressure and has already been successfully targeted by three major classes of antihypertensive drugs: by ACE inhibitors, by ARBs and by renin inhibitors. However, like other antihypertensives, they all have to be self-administered daily and don't provide a good solution for improving patient compliance. CYT006-AngQb is a therapeutic vaccine designed to instruct the patient’s immune system to produce a specific anti-angiotensin II antibody response. Angiotensin II is a small hormone in the body and part of the RAS. It causes blood vessels to narrow, resulting in an increase in blood pressure. Vaccination of humans with CYT006-AngQb has been shown to induce angiotensin II specific antibodies that should inhibit binding of angiotensin II to its receptors and thus reduce the narrowing of blood vessels. As first clinical data indicate, the achieved blood pressure reduction was particularly pronounced in the early morning when the vaccine effect suppressed the naturally occurring morning rise in blood pressure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinunknownNot AvailableHumanP30556 details
Type-2 angiotensin II receptorProteinunknownNot AvailableHumanP50052 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life4 months
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Drug InteractionsNot Available
Food InteractionsNot Available
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Experimental PropertiesNot Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available


Pharmacological action
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
Uniprot ID:
Molecular Weight:
41060.53 Da
Pharmacological action
General Function:
Receptor antagonist activity
Specific Function:
Receptor for angiotensin II. Cooperates with MTUS1 to inhibit ERK2 activation and cell proliferation.
Gene Name:
Uniprot ID:
Molecular Weight:
41183.45 Da
comments powered by Disqus
Drug created on November 18, 2007 11:27 / Updated on August 17, 2016 12:24